Dendreon and Charter Medical Announce Supply and Marketing Agreement for Stem Cell Enrichment Device.Business Editors, Health/Medical Writers SEATTLE--(BW HealthWire)--Aug. 10, 2000 Dendreon Corporation (Nasdaq:DNDN) and Lydall, Inc. (NYSE NYSE See: New York Stock Exchange :LDL LDL - ["LDL: A Logic-Based Data-Language", S. Tsur et al, Proc VLDB 1986, Kyoto Japan, Aug 1986, pp.33-41]. ) today announced the signing of a Supply and Marketing Agreement between Dendreon and Charter Medical, Ltd., a Lydall subsidiary, to distribute Dendreon's DACS DACS Data & Analysis Center for Software DACS Design and Analysis of Communication Systems (University of Twente, Netherlands) DACS Digital Access & Cross-Connect System DACS Data Acquisition and Control System (NASA) (R)SC medical device. Under the agreement, Charter Medical has been granted exclusive worldwide distribution rights for the DACS(R)SC stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. enrichment device -- a system designed and manufactured by Dendreon. The DACS(R)SC is used to isolate hematopoietic stem cells from blood for transplantation in cancer patients following high dose chemotherapy or radiation therapy. Stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young are used to restore the blood and immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Dendreon received Premarket Approval premarket approval Medical devices A scientific and regulatory review by the FDA to ensure the safety and effectiveness of a Class III device, before its approval for marketing. See Advisory panel, Medical device. (PMA PMA (papillary-marginal-attached), n a system of epidemiologic scoring of periodontal disease devised by Schour and Massler in which the symbols denote the areas involved in gingival inflammation. PMA Progressive muscular atrophy ) for the device from the U.S. Food and Drug Administration last year. "We are pleased to work with Charter Medical on the commercialization of the DACS(R)SC because of their expertise and established distribution channels in the blood processing field," said David Urdal, Ph.D., chief scientific officer of Dendreon. Dendreon's platform cell separation technology is designed to isolate cells rapidly, safely and cost effectively. It works by layering a mixture of cells over a specially formulated buoyant density solution in a patented two chamber separation container. Following centrifugation Centrifugation A mechanical method of separating immiscible liquids or solids from liquids by the application of centrifugal force. This force can be very great, and separations which proceed slowly by gravity can be speeded up enormously in centrifugal , cells separate based on their relative buoyant densities -- cells with low buoyant densities are found in the upper chamber, while cells with higher density are trapped in the bottom chamber of the container. "Charter Medical, Ltd. is excited about launching the DACS(R)SC with Dendreon," said Lisa Krallis-Nixon, general manager of Charter Medical. "We manufacture a variety of products designed to assist in stem cell collection and storage which complement the DACS(R)SC device. Our agreement with Dendreon enhances our strategic position as a vital fluids management company in the healthcare industry." Financial terms of the agreement were not disclosed. Charter Medical, Ltd. is a manufacturer of specialty products designed to manage vital fluids in the blood and biopharmaceutical industries. Lydall, Inc. is a manufacturer of engineered products for demanding specialty applications, primarily in thermal/acoustical materials and filtration/separation markets. Dendreon Corporation (www.dendreon.com), a biotechnology company headquartered in Seattle, Wash., is dedicated to the discovery and development of novel products for the treatment of cancer through its innovative manipulation of the immune system. Dendreon is focused on the development of therapeutic cancer vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine through the use of antigen discovery, antigen engineering and dendritic cell dendritic cell n. 1. A cell that has branching processes. 2. Any of the cells in the neural crest of the embryonic ectoderm having extensive processes and developing early as producers of melanin. technologies. Dendreon's vaccine for the treatment of prostate cancer (Provenge(TM)) is in Phase III clinical trials and its vaccine for the treatment of multiple myeloma (Mylovenge(TM)) is in Phase II clinical trials. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements. Factors that may cause such a difference include the risks of competition, changing market conditions, changes in laws and regulations affecting the medical device industry, customer acceptance of the product, dependence on the efforts of third parties, and dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's or Lydall's business, financial condition and results of operations, are contained in a) Dendreon's SEC Reports, including Dendreon's Form S-1, which is available at www.sec.gov; and b) in Lydall's 10-K, 10-Q and 8-K, available on Lydall's web site (www.lydall.com). Information regarding Lydall may also be obtained from Lydall's toll-free investor information service at 877-LDL-NYSE (535-6973). |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion